Compass Therapeutics (CMPX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CMPX Compass Therapeutics

Watchlist

1.450
-0.030-2.03%

Close Dec 31 16:00 ET

1.450
0.0000.00%

Post 16:02 ET

199.50MMarket Cap-4.14P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compass Therapeutics Initiated With a Buy at D. Boral Capital
TipRanksDec 23, 2024 07:20 ET · Ratings
Express News | D. Boral Capital Initiates Coverage On Compass Therapeutics With Buy Rating, Announces Price Target of $32
BenzingaDec 23, 2024 07:04 ET
Compass Therapeutics Names Barry Shin CFO
MT NewswiresDec 10, 2024 10:48 ET
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Yahoo FinanceDec 10, 2024 09:40 ET
Press Release: Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
Dow JonesDec 10, 2024 08:00 ET
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireDec 2, 2024 08:00 ET

Comments

Jaguar8

Oct 4, 2024 10:42

NEWS

$Compass Therapeutics (CMPX.US)$
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmaco...

Jaguar8

Apr 16, 2024 07:02

$Compass Therapeutics (CMPX.US)$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.

Moomoo Breakfast US

May 4, 2022 07:22

Columns Today's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more

Gainers:
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...

Heat List

Overall

No Data